Search / Trial NCT03508232

Doxycycline to Protect Heart Muscle After Heart Attacks
Launched by UNIVERSITY OF ALBERTA · Apr 24, 2018

Trial Information

Current as of May 22, 2025

Recruiting

Keywords

ClinConnect Summary

This clinical trial is studying whether a medication called doxycycline can help protect the heart muscle of patients who have experienced a heart attack. Heart attacks can cause damage to the heart, and some people may face ongoing heart problems afterward. Doxycycline, which is typically used to treat gum disease and certain skin conditions, has been shown in previous studies to potentially improve heart health when taken after a heart attack. In this trial, participants will receive standard treatment for heart attacks along with either doxycycline or a placebo (a pill that looks the same but has no active ingredients) for seven days. After three months, doctors will use a special imaging test called MRI to see how well the hearts of those who took doxycycline are doing compared to those who took the placebo.

To be eligible for this trial, participants must be at least 18 years old, have a specific type of heart attack (called ST-elevation myocardial infarction, or STEMI), and have experienced symptoms for less than 12 hours. They must also be admitted to the Royal Alexandra Hospital in Edmonton, Alberta. Throughout the study, participants can expect regular check-ups and monitoring of their heart health. This trial aims to determine if doxycycline can improve the quality of life for heart attack survivors, potentially leading to better heart health in the future.

Gender

ALL

Eligibility criteria

Inclusion Criteria:
• 1. 18+ year old
• 2. Diagnosis of acute ST-elevation myocardial infarction (STEMI)
• 3. Primary STEMI
• 4. Symptom onset of less than 12 hours
• 5. Admitted to the Royal Alexandra Hospital in Edmonton, Alberta
Exclusion Criteria:
• 1. Low risk inferior STEMI (total ST elevation plus depression \<4mm)
• 2. Cardiogenic shock
• 3. Use of thrombolytics
• 4. Prior history of myocardial infarction or heart failure
• 5. Known hypersensitivity to tetracyclines
• 6. Any concurrent medical condition expected to reduce life expectancy to \<1 year
• 7. Symptom onset to treatment (loading dose) time longer than 24 hours
• 8. Poor renal function (eGFR\<30 mL/min/1.73m2) or other contraindications to MRI (claustrophobia, pregnancy, PPM/ICD, sub-arachnoid clips, retained ocular foreign body)

About University Of Alberta

The University of Alberta, a leading research institution in Canada, is dedicated to advancing healthcare through innovative clinical trials. With a strong commitment to scientific excellence and community health, the university facilitates cutting-edge research across various medical disciplines. Its interdisciplinary approach fosters collaboration among researchers, clinicians, and students, ensuring that clinical trials are designed and conducted with the utmost rigor and ethical standards. By leveraging its extensive resources and expertise, the University of Alberta aims to translate research findings into meaningful advancements in patient care and public health.

Locations

Edmonton, Alberta, Canada

Patients applied

0 patients applied

Trial Officials

Richard Schulz, PhD

Study Chair

Dept. of Pediatrics and Pharmacology, University of Alberta

Peter Hwang, MD, PhD

Study Director